Challenges of accelerated vaccine development

Published on May 31, 2020   41 min

Other Talks in the Category: Immunology

0:00
My name's Jakub Simon and I'm the Director of Vaccines Clinical Research at Merck Research Laboratories. And today I'll be covering the Ebola vaccine story as a case study, to explore challenges and opportunities of accelerated vaccine development. And before we start, I would like you to take a moment to imagine yourself in an Ebola outbreak. People around you are getting sick, 6 people that you know got infected, 4 of them died and reflect on your thoughts. You want to leave the area, you'll like a treatment, you'll like a vaccine. How quickly would you like a treatment or vaccine available is the topic of today's discussion. And we'll cover the Ebola vaccine case study.
0:44
So we'll start by looking at vaccine development under normal circumstances, talk a little bit about Ebola. And the reason Ebola is a good case study is it that it covers all of the usual regulatory manufacturing non clinical and clinical development components that we'll explore.
1:01
Vaccine development under normal circumstances is a complex process that poses many challenges. The average development takes over 10 years and costs over $2 billion US, that is billion with a B. So if you just take two numbers, those two numbers and divide them you get over $200 million per year. The reason clinical development is so expensive, is because it is subject to rigorous oversight that includes testing by national regulatory authorities. And that is in order to ensure that the vaccines are safe, potent and effective each time that they're manufactured. And this is to address vaccine hesitancy and public distrust. Proactively, make sure that there aren't any problems with vaccines and medicines. Despite these challenges, one of the most cost effective means to prevent infectious diseases and contain outbreaks are vaccines.
Hide

Challenges of accelerated vaccine development

Embed in course/own notes